Additional file 1 of Amphipathic dendritic poly-peptides carrier to deliver antisense oligonucleotides against multi-drug resistant bacteria in vitro and in vivo

Additional file 1: Figure S1. The HPLC and mass spectra of DPP1-DPP6. Figure S2. The HPLC and mass spectra of DPP7-DPP12. Figure S3. The identification of L-DPP, ASOs, and DSPE-mPEG2000. Figure S4. The screening of the N/P ratio of ADs. Figure S5. The encapsulation of ASOs and binding rate of DSPE-mPEG2000 in the nanoparticles. Figure S6. Screening the molar ratio of DSPE-mPEG2000 in DP-AD. Figure S7. The characteristics of the nanoparticles. Figure S8. The serum stability of DP-AD. Figure S9. Uptake efficiencies and growth curves of DP-AD in E. coli and S. aureus. Figure S10. Uptake profiles of DP-AD by E. coli and S. aureus. Figure S11. The cytotoxicity and hemolytic activity of DP-AD. Figure S12. Uptake efficiencies of DP-AD7 incubated at different temperature. Figure S13. Growth inhibitory effect of DP-AD7anti-acpP in bacteria. Figure S14. Gene expression effect of DP-AD7anti-acpP or DP-AD7anti-rpoD in bacteria. Figure S15. Histological morphology of the organs. Table S1. The sequences, property and the number of His residues of DPPs. Table S2. The purity, m/z values and positive charge number of DPPs. Table S3. The solvents and concentration of store solutions of DPPs. Table S4. The size and zeta potential of DP-AD. Table S5. The positive ratio of bacteria after co-incubating with FAM-labeled DP-AD. Table S6. The minimum inhibitory concentration of DPPs to bacteria.